ISSN: 2642-6315
Authors: Iakushina SA* and Bazyleva EV
Adoptive T-cell immunotherapy is one of the targeted immunological methods that have received widespread use in the treatment of oncological diseases. The most used cell platform is CD8+ cytotoxic lymphocytes, in addition to CD4+ and NK cells. The method has the specificity of monoclonal antibodies and minimal side effects. Both cytotoxic T-cell (CTL) and cells containing the chimeric antigen receptor (CAR)-receptor are used. Immunotherapy cells can be obtained from both the patient (autotransplantation) and the donor (allotransplantation). Attempts are being made to create T-cells that do not require HLA-matching and are not taken from the patient so that they can be simpler and cheaper to use. Over time, the scope of application of cytotoxic T cells in the treatment of not only oncological but virus-associated diseases has been expanding. However, the methodology still does not have standard generally accepted protocols, and their development is a big task for the future.
Keywords: Adoptive T-cell Immunotherapy; Chimeric Antigen Receptor; Cancer; Lymphoma; Epstein - Barr virus; Cytomegalovirus
